Search

Displaying results 3091 - 3100 of 6835 in total
  1. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  2. Drug

    Clotiazepam

    go.drugbank.com/drugs/DB01559
    ApprovedIllicit

    Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

  3. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite. … falciparum malaria that is resistant to other antimalarials.

    Synonyms: Lumefantrine co-artemether
  4. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.

  5. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.

  6. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.

  7. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). … The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the

    Categories: Agents to Treat Airway Disease
  8. Drug

    Indigotindisulfonic acid

    go.drugbank.com/drugs/DB11577
    ApprovedInvestigational

    [A251405] Indigotindisulfonic acid is used in clinical medicine to determine patency of the urinary collecting system, and to assist in specific surgical procedures such as cystourethroscopy. … [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to aid in visualizing ureter integrity in cystoscopic assessments.[L42600]

  9. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.

  10. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.